Sage TherapeuticsSAGE
SAGE
About: Sage Therapeutics Inc is a clinical-stage biopharmaceutical company focused on brain health medicines. The company is targeting diseases and disorders of the brain with three key focus areas: depression, neurology and neuropsychiatry; also targeting two critical central nervous system, or CNS, receptor systems, GABA and NMDA. Its products ZURZUVAE is a medicine for the treatment of postpartum depression, or PPD, in adults, and ZULRESSO is a CIV injection for the treatment of postpartum depression in individuals 15 years old and older. It also has other drugs in its pipeline such as SAGE-324, Dalzanemdor (SAGE-718) among others.
Employees: 487
0
Funds holding %
of 7,425 funds
0
Analysts bullish %
of 4 analysts
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
150% more call options, than puts
Call options by funds: $2.74M | Put options by funds: $1.1M
4% more first-time investments, than exits
New positions opened: 25 | Existing positions closed: 24
1% more funds holding
Funds holding: 175 [Q3] → 176 (+1) [Q4]
0.5% less ownership
Funds ownership: 84.24% [Q3] → 83.74% (-0.5%) [Q4]
10% less repeat investments, than reductions
Existing positions increased: 52 | Existing positions reduced: 58
26% less capital invested
Capital invested by funds: $374M [Q3] → $278M (-$95.5M) [Q4]
Research analyst outlook
4 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$6
18%
downside
Avg. target
$9.50
30%
upside
High target
$12
65%
upside
4 analyst ratings
1 positive
25%
3 neutral
75%
0 negative
0%
Scotiabank George Farmer 19% 1-year accuracy 4 / 21 met price target | 65%upside $12 | Sector Outperform Maintained | 12 Feb 2025 |
Wedbush Laura Chico 13% 1-year accuracy 6 / 47 met price target | 18%downside $6 | Neutral Reiterated | 12 Feb 2025 |
Canaccord Genuity Sumant Kulkarni 10% 1-year accuracy 3 / 29 met price target | 10%upside $8 | Hold Maintained | 12 Feb 2025 |
HC Wainwright & Co. Douglas Tsao 26% 1-year accuracy 44 / 171 met price target | 65%upside $12 | Neutral Reiterated | 12 Feb 2025 |
Financial journalist opinion
Based on 20 articles about SAGE published over the past 30 days
Negative
Zacks Investment Research
15 hours ago
Sage Therapeutics' Q1 Earnings Miss Mark, Revenue Rise Y/Y
SAGE's earnings and revenues miss estimates in the first quarter of 2025. The company focuses on the commercialization of its depression drug Zurzuvae.
Neutral
Seeking Alpha
1 day ago
Sage Therapeutics, Inc. (SAGE) Q1 2025 Earnings Call Transcript
Sage Therapeutics, Inc. (NASDAQ:SAGE ) Q1 2025 Earnings Call April 29, 2025 4:30 PM ET Company Participants Ashley Kaplowitz - Investor Relations Barry Greene - Chief Executive Officer Chris Benecchi - Chief Operating Officer Mike Quirk - Chief Scientific Officer and Interim Head, R&D Conference Call Participants Malcolm Kuno - JPMorgan Shrunatra Mishra - Goldman Sachs Morgan Gryga - Morgan Stanley Ami Fadia - Needham Brian Abrahams - RBC Capital Markets David Amsellem - Piper Sandler Douglas Tsao - H.C. Wainwright Uy Ear - Mizuho Joel Beatty - Baird Laura Chico - Wedbush Securities Basma Radwan - Leerink Partners Sumant Kulkarni - Canaccord Asim Rana - Truist Securities Operator Good afternoon.
Negative
Zacks Investment Research
1 day ago
Sage Therapeutics, Inc. (SAGE) Reports Q1 Loss, Misses Revenue Estimates
Sage Therapeutics, Inc. (SAGE) came out with a quarterly loss of $1.01 per share versus the Zacks Consensus Estimate of a loss of $0.99. This compares to loss of $1.80 per share a year ago.
Neutral
Business Wire
1 day ago
Sage Therapeutics Announces First Quarter 2025 Financial Results and Highlights Pipeline and Business Updates
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sage Therapeutics, Inc. (Nasdaq: SAGE), today reported business highlights and financial results for the first quarter ended March 31, 2025. “We delivered strong growth in revenue and shipments of ZURZUVAE during the first quarter of 2025 through the team's disciplined execution and unwavering commitment to bringing ZURZUVAE to more women with postpartum depression,” said Barry Greene, Chief Executive Officer at Sage Therapeutics. “We remain focused on establi.
Neutral
Accesswire
1 day ago
Bronstein, Gewirtz & Grossman, LLC Encourages Sage Therapeutics, Inc. (SAGE) Shareholders to Inquire about Securities Investigation
NEW YORK CITY, NY / ACCESS Newswire / April 29, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Sage Therapeutics, Inc. ("Sage" or "the Company") (NASDAQ:SAGE). Investors who purchased Sage securities prior to April 12, 2021, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/SAGE.
Neutral
Accesswire
6 days ago
Bronstein, Gewirtz & Grossman, LLC Encourages Sage Therapeutics, Inc. (SAGE) Stockholders to Inquire about Securities Investigation
NEW YORK CITY, NY / ACCESS Newswire / April 24, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Sage Therapeutics, Inc. ("Sage" or "the Company") (NASDAQ:SAGE). Investors who purchased Sage securities prior to April 12, 2021, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/SAGE.
Neutral
PRNewsWire
1 week ago
Kuehn Law Encourages Investors of Sage Therapeutics, Inc. to Contact Law Firm
NEW YORK , April 22, 2025 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Sage Therapeutics, Inc. (NASDAQ: SAGE) breached their fiduciary duties to shareholders. According to a federal securities lawsuit, Sage insiders caused the company to misrepresent or fail to disclose that (i) zuranolone was less effective in treating MDD than the company had led investors to believe; (ii) accordingly, the FDA was unlikely to approve the Zuranolone NDA for the treatment of MDD in its present form, and zuranolone's clinical results for MDD, as well as its overall regulatory and commercial prospects, were overstated; (iii) SAGE-718 was less effective in treating MCI due to PD than the company had led investors to believe; (iv) accordingly, SAGE-718's clinical, regulatory, and commercial prospects as a treatment for MCI due to PD were overstated; (v) SAGE-324 was less effective in treating ET than the company had led investors to believe; (vi) accordingly, SAGE-324's clinical, regulatory, and commercial prospects as a treatment for ET were overstated; and (vii) as a result of all the foregoing, the company's public statements were materially false and misleading at all relevant times.
Negative
Zacks Investment Research
1 week ago
Sage Therapeutics, Inc. (SAGE) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
Sage Therapeutics (SAGE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Neutral
Accesswire
1 week ago
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Sage Therapeutics, Inc. (SAGE) and Encourages Investors to Learn More About the Investigation
NEW YORK CITY, NY / ACCESS Newswire / April 22, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Sage Therapeutics, Inc. ("Sage" or "the Company") (NASDAQ:SAGE). Investors who purchased Sage securities prior to April 12, 2021, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/SAGE.
Neutral
Accesswire
1 week ago
Sage Therapeutics, Inc. (SAGE) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation
NEW YORK CITY, NY / ACCESS Newswire / April 20, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Sage Therapeutics, Inc. ("Sage" or "the Company") (NASDAQ:SAGE). Investors who purchased Sage securities prior to April 12, 2021, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/SAGE.
Charts implemented using Lightweight Charts™